Aravive Investor Presentation Deck

Aravive Pipeline Opportunity for Expansion into Additional Indications and Drug Combinations Indication Batiraxcept (AVB-500) OVARIAN CANCER Platinum Resistant (batiraxcept + paclitaxel) CLEAR CELL RENAL CANCER 1st Line (batiraxcept + cabozantinib + nivolumab) 2nd Line (batiraxcept + cabozantinib) Ineligible for curative intent therapy (batiraxcept monotherapy) ■ PANCREATIC ADENOCARCINOMA 1 Line (batiraxcept + gemcitabine + nab-paclitaxel) Preclinical Phase 1 Phase 2 Fast-Track Designation in U.S., Orphan Designation in EU Phase 3 10

View entire presentation